Invivyd was founded by Marc Elia.

Who are Invivyd's investors?

Invivyd's investors include Bain Capital Life Sciences, Foresite Capital, MRL Ventures Fund, Premji Invest, RA Capital, GV (Google Ventures), Mithril Capital Management, OrbiMed and 1 more.

Invivyd

NASDAQ: IVVDUnicorn · $1.5B

9 known investors

Find your way into Invivyd

Each arrow is one introduction. Sign up to fill in the first one.

105 people can intro you to Marc

Ask Daniel Jacobs to introduce you to Marc Elia

You →Daniel · together at Bridger Capital LLC →Marc

Your email: who you already know at Invivyd, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Invivyd team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications. It uses a proprietary integrated technology platform to design antibodies that are more potent and resistant to viral evolution.

Biotech Healthtech

Founders & leadership

Marc Elia Founder · Chairman of the BoardMarc Elia has served as Chairman of the Board of Invivyd since June 2022. The company develops monoclonal antibody medicines to prevent and treat serious viral infectious diseases such as COVID-19.

Investors · 9

Bain Capital Life Scienceslisted by Bain Capital Life SciencesBoston

How we know: Bain Capital Life Sciences's portfolio page · Not right? Tell us

Foresite Capitallisted by Foresite CapitalWest Hollywood

How we know: Foresite Capital's portfolio page · Not right? Tell us

MRL Ventures Fundlisted by MRL Ventures FundCambridge · $25M

How we know: MRL Ventures Fund's portfolio page · Not right? Tell us

Premji Investlisted by Premji InvestMenlo Park

RA Capitallisted by RA CapitalBoston

How we know: RA Capital's portfolio page · the S-1 prospectus · a partner's Signal profile · Not right? Tell us

GV (Google Ventures)reportedMountain View · $250K – $50M

How we know: the S-1 prospectus · Not right? Tell us

Mithril Capital ManagementreportedAustin

How we know: funding news · Not right? Tell us

OrbiMedreportedNew York · $1M – $75M

How we know: the S-1 prospectus · Not right? Tell us

Polaris PartnersreportedBoston · $500K – $5M

How we know: a partner's Signal profile · Not right? Tell us

Valuation · disclosed

Disclosed events

$1.5Bvaluation at IPOAug 2021 · $17.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Founder mafia

2 people who came through Invivyd went on to found or lead other companies.

Jeremy GowlerChief Operating Officer & Chief Commercial OfficerFounded Ophirex Paul B. Bolno, M.D.Independent DirectorFounded Wave Life Sciences

Related companies · 4

IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.

NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.

Companies working in the same space as Invivyd.

In the news

Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY | Invivydinvestors.invivyd.com · Sep 2026

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights - BioSpacebiospace.com · Jan 2026

Frequently asked questions

What does Invivyd do?: Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications. It uses a proprietary integrated technology platform to design antibodies that are more potent and resistant to viral evolution.
Who founded Invivyd?: Invivyd was founded by Marc Elia.
Who are Invivyd's investors?: Invivyd's investors include Bain Capital Life Sciences, Foresite Capital, MRL Ventures Fund, Premji Invest, RA Capital, GV (Google Ventures), Mithril Capital Management, OrbiMed and 1 more.